{"id":"i-v-palonosetron","safety":{"commonSideEffects":[{"rate":"5–9","effect":"Headache"},{"rate":"3–5","effect":"Constipation"},{"rate":"2–4","effect":"Diarrhea"},{"rate":"1–3","effect":"Dizziness"},{"rate":"1–2","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Palonosetron binds with high affinity and selectivity to 5-hydroxytryptamine type 3 (5-HT3) receptors, which are located on vagal afferents in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By antagonizing these receptors, it prevents the emetic signals triggered by chemotherapy, radiation, or post-operative conditions from reaching the vomiting center.","oneSentence":"Palonosetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:15:21.212Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Prevention of post-operative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT07480785","phase":"NA","title":"TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2026-01-16","conditions":"Uterine Fibroids (Leiomyoma), Ovarian Tumors, Gallstones","enrollment":780},{"nctId":"NCT01363479","phase":"PHASE3","title":"An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2011-07","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":743},{"nctId":"NCT03933605","phase":"NA","title":"Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy","status":"COMPLETED","sponsor":"Yeungnam University College of Medicine","startDate":"2017-07-10","conditions":"Postoperative Nausea, Postoperative Vomiting","enrollment":88},{"nctId":"NCT02557035","phase":"PHASE3","title":"An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2015-10","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":441},{"nctId":"NCT00982995","phase":"PHASE2","title":"Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2010-11","conditions":"Nausea, Vomiting, Terminally Ill","enrollment":3},{"nctId":"NCT00636805","phase":"PHASE2","title":"Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab","status":"TERMINATED","sponsor":"Duke University","startDate":"2008-05","conditions":"Brain Cancer","enrollment":63},{"nctId":"NCT01088022","phase":"PHASE3","title":"Aprepitant for Prevention of Acute and Delayed Nausea and Vomiting in Patients Receiving a High-emetogenic Dose of Cyclophosphamide for Peripheral Blood Stem Cells Harvesting","status":"UNKNOWN","sponsor":"Azienda Ospedaliera di Perugia","startDate":"2010-04","conditions":"Nausea, Vomiting","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"I.V. palonosetron","genericName":"I.V. palonosetron","companyName":"Helsinn Healthcare SA","companyId":"helsinn-healthcare-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Palonosetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV), Prevention of post-operative nausea and vomiting (PONV).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}